Content about Rhinitis

April 18, 2014

Merck on Thursday announced that the Food and Drug Administration has approved Ragwitek (short ragweed pollen allergen extract) tablet for sublingual use (12 Amb a 1-U).

WHITEHOUSE STATION, N.J. — Merck on Thursday announced that the Food and Drug Administration has approved Ragwitek (short ragweed pollen allergen extract) tablet for sublingual use (12 Amb a 1-U). Ragwitek is an allergen extract indicated as immunotherapy for the treatment of short ragweed pollen-induced allergic rhinitis with or without conjunctivitis. Ragwitek is approved for use in adults ages 18 years through 65 years. 

April 15, 2014

The Food and Drug Administration on Friday announced a meeting of the Nonprescription Drugs Advisory Committee on May 2 to discuss the potential switch of Merck's Singulair Allergy tablets.

SILVER SPRING, Md. — The Food and Drug Administration on Friday announced a meeting of the Nonprescription Drugs Advisory Committee on May 2 to discuss the potential switch of Merck's Singulair Allergy tablets. 

The proposed OTC use is "temporarily relieves these symptoms due to hay fever or other upper respiratory allergies: Nasal congestion, runny nose, itchy, watery eyes, sneezing, itching of the nose.” The applicant proposes to label the product for OTC use in adults 18 years and older. 

April 15, 2014

Merck announced that the Food and Drug Administration has approved Grastek (Timothy grass pollen allergen extract) tablet for sublingual use.

WHITEHOUSE STATION, N.J. — Merck announced that the Food and Drug Administration has approved Grastek (Timothy grass pollen allergen extract) tablet for sublingual use. The drug is an allergen extract used for the treatment of grass pollen-induced allergic rhinitis with or without conjunctivitis. It is approved for use in persons ages 5 years through 65 years of age.

March 26, 2014

Springtime allergy season may be delayed a few weeks this year, kicking into high gear in early April as opposed to late March due to a 2013-2014 winter characterized by extremely low temperatures and heavy snow storms.

Springtime allergy season may be delayed a few weeks this year, kicking into high gear in early April as opposed to late March due to a 2013-2014 winter characterized by extremely low temperatures and heavy snow storms. 

January 27, 2014

The Food and Drug Administration will hold a public meeting of the Allergenic Products Advisory Committee on Tuesday to determine the safety and efficacy of Ragwitek, a short ragweed pollen allergen extract tablet for sublingual use.

ARLINGTON HEIGHTS, Ill. — The Food and Drug Administration will hold a public meeting of the Allergenic Products Advisory Committee on Tuesday to determine the safety and efficacy of Ragwitek, a short ragweed pollen allergen extract tablet for sublingual use, which is manufactured by Merck and indicated for immunotherapy for diagnosed ragweed pollen induced allergic rhinitis, with or without conjunctivitis.

November 8, 2013

A study being presented this week at the Annual Scientific Meeting of the American College of Allergy, Asthma and Immunology found hay fever is more prevalent in children living in the southeastern and southern states, ACAAI announced Friday.

BALTIMORE — A study being presented this week at the Annual Scientific Meeting of the American College of Allergy, Asthma and Immunology found hay fever is more prevalent in children living in the southeastern and southern states, ACAAI announced Friday.

April 3, 2013

The Food and Drug Administration has approved a new drug for allergies in children made by Tris Pharma, the drug maker said.

MONMOUTH JUNCTION, N.J. — The Food and Drug Administration has approved a new drug for allergies in children made by Tris Pharma, the drug maker said Wednesday.

Tris announced the approval of Karbinal ER (carbinoxamine maleate) extended-release oral suspension in the 4 mg-per-five milliliter strength. The company said the drug was the first sustained-release histamine receptor blocking agent for seasonal and perennial allergic rhinitis in children 2 and older.

February 25, 2013

As spring approaches, people with allergies can blame global warming for some of their suffering, according to the American College of Allergy, Asthma and Immunology. Weather conditions have a significant effect on the levels of pollen and mold in the air, which affects the severity of allergies.

As spring approaches, people with allergies can blame global warming for some of their suffering, according to the American College of Allergy, Asthma and Immunology. Weather conditions have a significant effect on the levels of pollen and mold in the air, which affects the severity of allergies.

That suggests mold allergens could be particularly prominent this spring given the extent of drought across the United States — dry and hot weather lifts molds from the soil to be carried by the air. In addition to tree pollen, springtime mold contributes to hay fever.

November 29, 2012

Valeant Consumer Products recently announced that its line of Ocean Saline Nasal Sprays have been the most recommended by pharmacists for 15 years running. 


SUPPLIER NEWS — Valeant Consumer Products recently announced that its line of Ocean Saline Nasal Sprays have been the most recommended by pharmacists for 15 years running. 


Ocean offers nonmedicated relief from dry and irritated nasal passages due to allergies, colds, flu, sinusitis and rhinitis. The nasal spray is gentle enough for infants and has three delivery options — standing the bottle upright delivers a spray; horizontally, a stream; and upside-down, a drop. 


November 8, 2012

Valeant Consumer Products recently announced that its line of Ocean Saline Nasal Sprays has been the most recommended by pharmacists for 15 years running.

BRIDGEWATER, N.J. — Valeant Consumer Products recently announced that its line of Ocean Saline Nasal Sprays has been the most recommended by pharmacists for 15 years running. 

Ocean offers nonmedicated relief from dry and irritated nasal passages due to allergies, colds, flu, sinusitis and rhinitis. The nasal spray is gentle enough for infants and has three delivery options — standing the bottle upright delivers a spray; horizontally, a stream; and upside-down, a drop. 

August 16, 2012

According to the American College of Allergy, Asthma and Immunology, 25 million adults and children across the country were diagnosed with rhinitis, or hay fever, within the last 12 months, which may lead many to believe they’ve caught an early-season cold.

ARLINGTON HEIGHTS, Ill. — According to the American College of Allergy, Asthma and Immunology, 25 million adults and children across the country were diagnosed with rhinitis, or hay fever, within the last 12 months, which may lead many to believe they’ve caught an early-season cold.

March 26, 2012

The Food and Drug Administration has approved a drug made by Teva for treating allergies, the company said Monday.

JERUSALEM — The Food and Drug Administration has approved a drug made by Teva for treating allergies, the company said Monday.

Teva announced the approval of Qnasl (beclomethasone dipropionate) for seasonal and year-round nasal allergies in patients ages 12 years and older. The company said the drug, a "dry" nasal aerosol, would become available next month.

February 24, 2012

In preparation for spring, the American College of Allergy, Asthma and Immunology on Friday noted that avoiding certain fruits and vegetables, installing the proper air filters, closing the windows, filling any allergy prescriptions and consulting with an allergist can all prevent the delay of allergy symptom relief for more than 35 million Americans who suffer from seasonal allergies.

ARLINGTON HEIGHTS, Ill. — In preparation for spring, the American College of Allergy, Asthma and Immunology on Friday noted that avoiding certain fruits and vegetables, installing the proper air filters, closing the windows, filling any allergy prescriptions and consulting with an allergist can all prevent the delay of allergy symptom relief for more than 35 million Americans who suffer from seasonal allergies.

August 8, 2011

The Food and Drug Administration has accepted an approval application for a drug made by Teva Pharmaceutical Industries for treating allergies, Teva said.

JERUSALEM — The Food and Drug Administration has accepted an approval application for a drug made by Teva Pharmaceutical Industries for treating allergies, Teva said.

The Israeli drug maker said the FDA accepted its application for BDP Nasal HFA (beclomethasone dipropionate hydrofluoroalkane) for the treatment of seasonal allergic rhinitis and perennial allergic rhinitis. The drug is a nasal aerosol corticosteroid.

May 10, 2011

Patients with seasonal allergies are more likely to experience difficulty sleeping, according to results of a new survey conducted by Teva Respiratory.

HORSHAM, Pa. — Patients with seasonal allergies are more likely to experience difficulty sleeping, according to results of a new survey conducted by Teva Respiratory.

March 22, 2011

Less than 20% of surveyed patients with nasal allergies find their symptoms are completely controlled over a one-week period of treatment, according to a survey performed by drug maker Teva Pharmaceutical Industries.

SAN FRANCISCO — Less than 20% of surveyed patients with nasal allergies find their symptoms are completely controlled over a one-week period of treatment, according to a survey performed by drug maker Teva Pharmaceutical Industries.

February 9, 2011

An investigational drug made by Teva Pharmaceutical Industries for treating allergies is safe and effective, according to results of a late-stage clinical trial announced Wednesday.

JERUSALEM — An investigational drug made by Teva Pharmaceutical Industries for treating allergies is safe and effective, according to results of a late-stage clinical trial announced Wednesday.

Teva said the phase-3 trial of the nasally inhaled drug Qnaze (beclomethasone dipropionate) showed that it significantly relieved symptoms of seasonal and perennial allergic rhinitis compared with placebo while demonstrating a similar safety profile.

November 15, 2010

An investigative treatment for allergies made by Teva Pharmaceutical Industries appears to work, according to...

JERUSALEM — An investigative treatment for allergies made by Teva Pharmaceutical Industries appears to work, according to results of a late-stage clinical trial released Monday.

 

Teva said phase-3 data from a study of Qnaze HFA (beclomethasone dipropionate), designed to be inhaled through the nose, was effective in treating patients with seasonal allergic rhinitis, while safety results were similar to those for placebo. Data from the study were presented at the annual meeting of the American College of Allergy, Asthma & Immunology in Phoenix.